Escalating interferon-a-2b dose for patients with chronic hepatitis C

Hepato-Gastroenterology

Volumn 45, Issue 24, 1998, Pages 2308-2314

  De La Riva, Elizabeth ^a   Garcia Carrasquillo, Reuben J ^a   Puppo, Mary D ^a   Mustacchia, Paul J ^a   Factor, Stephanie ^a   Joe, Andrew ^a   Finegold, Jonathan ^a   Riley, Thomas H ^a   Sarabanchong, Viyada ^a   Ligresti, Rosario J ^a   Markowitz, David D ^a   McMahon, Donald J ^a   Magun, Arthur M ^a   Worman, Howard J ^a  

^a Columbia University ^*  (United States)

Author keywords

Alpha interferon; Liver diseases; Viral hepatitis

Indexed keywords

ALANINE AMINOTRANSFERASE; RECOMBINANT ALPHA2B INTERFERON; ALPHA2B INTERFERON; VIRUS RNA;

ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; CHRONIC HEPATITIS; FEMALE; HEPATITIS C; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; SIDE EFFECT; BLOOD; DOSE RESPONSE; DRUG ADMINISTRATION; DRUG EFFECT; FOLLOW UP; HEPATITIS C VIRUS; LIVER FUNCTION TEST; MIDDLE AGED; TREATMENT OUTCOME; VIRUS REPLICATION;

ADULT; AGED; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; FOLLOW-UP STUDIES; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; INTERFERON ALFA-2B; LIVER FUNCTION TESTS; MALE; MIDDLE AGED; RNA, VIRAL; TREATMENT OUTCOME; VIRUS REPLICATION;

EID: 0032216692     PISSN: 01726390     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (27)

1. Hoofnagle JH, Mullen DK, Jones DB, et al: Treatment of chronic non-A, non-B hepatitis with recombinant human alfa Interferon: a preliminary report. N Engl J Med 1986; 315:1575-1578.
2. Davis GL, Balart LA, Schiff ER, et al: Treatment of chronic hepatitis C with recombinant interferon alfa: a multicenter randomized, controlled clinical trial. N Engl J Med 1989; 321:1501-1506.
3. Di Bisceglie AM, Martin P, Kassianides C, et al: Recombinant interferon alfa therapy for chronic hepatitis C: a randomized, double-blind, placebo-controlled trial. N Engl J Med 1989; 321:1506-1510.
4. Hoofnagle JH, Di Bisceglie AM: The treatment of chronic viral hepatitis. N Engl J Med 1997; 336:347-356.
5. Poynard T, Bedossa P, Chevallier M, et al: A comparison of three interferon alfa-2b regimens for the long-term treatment of chronic non-A, non-B hepatitis. N Engl J Med 1995; 332:1457-1462.
6. Poynard T, Leroy V, Cohard M, et al: Meta-analysis of interferon randomized trials in the treatment of viral hepatitis C: effects of dose and duration. Hepatol 1996; 24:778-789.
7. Tsubota A, Chayama K, Ikeda K, et al: Factors predictive of response to interferon-a therapy in hepatitis C infection. Hepatol 1994; 19:1088-1094.
8. Jouet P, Roudot-Thoraval F, Dhumeaux, D, et al: Comparative efficacy of interferon alfa in cirrhotic and noncirrhotic patients with non-A, non-B, C hepatitis. Gastroenterol 1994; 106:686-690.
9. Davis GL: Prediction of response to interferon treatment of chronic hepatitis. J Hepatol 1994; 21:1-3.
10. Enomoto N, Sakuma I, Asahina Y, et al: Mutations in the nonstructural protein 5A gene and response to interferon in patients with chronic hepatitis C virus 1b infection. N Engl J Med 1996; 334:77-81.
11. Marcellin P, Routeau M, Martinot-Peignoux M, et al: Lack of benefit of escalating dosage of interferon alfa in patients with chronic hepatitis C. Gastroenterol 1995; 109:156-165.
12. Lindsay KL, Davis GL, Schiff ER, et al: Response to higher doses of interferon alfa-2b in patients with chronic hepatitis C: a randomized multicenter trial. Hepatol 1996; 24:1034-1040.
13. Van Thiel DH, Friedlander L, Molloy RJ, et al: Retreatment of hepatitis C interferon non-responders with larger doses of interferon with and without phlebotomy. Hepato-Gastroenterol 1996; 43:1557-1561.
14. Fleiss, JL: Statistical Methods for Rates and Proportions. John Wiley & Sons, New York, 1981.
15. Davis GL, Lindsay K, Albrecht J, et al: Clinical predictors of response to recombinant alpha interferon treatment in patients with chronic non-A, non-B hepatitis (hepatitis C). J Viral Hepat 1994; 1:55-63.
16. Toyoda H, Nakano S, Kumada T, et al: Effect of daily administration period of natural α-interferon in patients with chronic hepatitis C. Am J Gastroenterol 1996; 91:743-747.
17. Hoofnagle JH, Peters M, Mullen KD, et al: Randomized, controlled trial of recombinant human alpha-interferon in patients with chronic hepatitis B. Gastroenterol 1988; 95:1318-1325.
18. Perrillo RP, Schiff ER, Davis GL, et al: Randomized, controlled trial interferon alfa-2b alone and after prednisone withdrawal for the treatment of chronic hepatitis B. N Engl J Med 1990; 323:295-301.
19. Di Bisceglie AM, Fong T, Fried MW, et al: A randomized, controlled trial of recombinant alpha-interferon therapy for chronic hepatitis B. Am J Gastroenterol 1993; 88:1887-1892.
20. Schiffman ML, Hofmann CM, Thompson EB, et al: Relationship between biochemical, virological and histological response during interferon treatment of chronic hepatitis C. Hepatol 1997; 26:780-785.
21. Nishiguchi S, Kuroki T, Nakatani S, et al: Randomised trial of effects of interferon-a on incidence of hepatocellular carcinoma in chronic active hepatitis C with cirrhosis. Lancet 1995; 346:1051-1055.
22. Lai MY, Kao JH, Yang PM, et al: Long-term efficacy of ribavirin plus interferon alfa in the treatment of chronic hepatitis C. Gastroenterol 1996; 111:1307-1312.
23. Reichard O, Norkrans G, Fryden A, et al: Randomised, double-blind, placebo-controlled trial of interferon alpha-2b with and without ribavirin for chronic hepatitis C. Lancet 1998; 351:83-87.
24. Love RA, Parge HE, Wickersham JA, et al: The crystal structure of hepatitis C virus NS3 proteinase reveals a trypsin-like fold and a structural zinc binding site. Cell 1996; 87:331-342.
25. Kim JL, Morgenstern KA, Lin C, et al: Crystal structure of the hepatitis C virus NS3 protease domain complexed with a synthetic NS4A cofactor peptide. Cell 1996; 87:343-355.
26. Yao N, Hesson T, Cable M, et al: Structure of the hepatitis C virus RNA helicase domain. Nature Struct Biol 1997; 4:463-467.
27. Kim JL, Morgenstern KA, Griffith JP, et al: Hepatitis C virus NS3 RNA helicase domain with a bound oligonucleotide: the crystal structure provides insights into the mode of unwinding. Structure 1998; 6:89-100.